A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

This study is testing a combination of two drugs — epcoritamab (a bispecific antibody that directs immune cells to kill lymphoma cells) and ibrutinib (a targeted cancer drug) — in people with central nervous system lymphoma (CNSL), a rare and aggressive blood cancer that develops in or has spread to the brain or spinal fluid. **You may be eligible if...** - You are 18 or older with confirmed large B-cell lymphoma involving the brain or central nervous system (CNS) that has returned or not responded to prior treatment - Your general health is acceptable (ECOG 0–2) and your organ function meets study standards - You are not newly diagnosed — this study is for relapsed or refractory CNS lymphoma **You may NOT be eligible if...** - You are currently taking warfarin or strong blood thinners that cannot be stopped - You have significant heart disease, HIV, active hepatitis B or C, or an uncontrolled infection - You have had recent chemotherapy or radiation to the CNS (within 4 weeks or 21 days respectively) - You are pregnant or breastfeeding - You have another active cancer requiring treatment Talk to your doctor to see if this trial is right for you.